Canaccord Genuity Maintains a 'Buy' on Cytokinetics (CYTK); Focus on New CK357 ALS Phase 2 Data at AAN in April
Go back to Canaccord Genuity Maintains a 'Buy' on Cytokinetics (CYTK); Focus on New CK357 ALS Phase 2 Data at AAN in April| Amgen Inc (NASDAQ: AMGN) | Delayed: 438.12 +8.24 (1.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $429.88 | 52 Week High | $176.85 | |||
| Open | $435.30 | 52 Week Low | $133.64 | |||
| Day High | $438.65 | P/E | 65.98 | |||
| Day Low | $431.00 | EPS | $6.64 | |||
| Volume | 2,358,996 | |||||
| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 71.40 +0.49 (0.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $70.91 | 52 Week High | $13.18 | |||
| Open | $69.85 | 52 Week Low | $6.00 | |||
| Day High | $72.46 | P/E | N/A | |||
| Day Low | $69.83 | EPS | $-1.24 | |||
| Volume | 1,898,311 | |||||
